Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: A Phase I study

British Journal of Cancer

Volumn 96, Issue 1, 2007, Pages 38-43

  Sheikh, H Y ^a   Valle, J W ^a   Palmer, K ^a   Sjursen, A ^a   Craven, O ^a   Wilson, G ^a   Swindell, R ^a   Saunders, M P ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Advanced colorectal cancer; CPT 11; Irinotecan; Oxaliplatin; Tegafur uracil; UFT

Indexed keywords

FOLINIC ACID; IRINOTECAN; OXALIPLATIN; UFT;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DIARRHEA; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HEART; HUMAN; INFECTION; LETHARGY; LEUKOPENIA; MALE; MAXIMUM TOLERATED DOSE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; VOMITING; WORLD HEALTH ORGANIZATION;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; SURVIVAL RATE; TEGAFUR; TREATMENT OUTCOME; URACIL;

EID: 33846206917     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603521     Document Type: Article

References (19)

1. Alonso V, Escudero P, Grandez R, Alvarez I, Ruiz de Lobera A, Polo E, Corral M, Lara R, Puertolas T, Anton A (2003) Weekly irinotecan (CPT11) combined with uracil-tegafur (UFT) as first-line treatment for metastatic colorectal cancer. Proc Am Soc Clin Oncol 22, abstr 1344
2. Bennouna J, Perrier H, Paillot B, Priou F, Jacob JH, Hebbar M, Bordenave S, Seitz JF, Cvitkovic F, Dorval E, Malek K, Tonelli D, Douillard JY (2006) A phase II study of oral uracil/ftorafur (UFT) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer. Br J Cancer 16(94): 69-73
3. Borner M, Schoffski P, de Wit R, Caponigro F, Comella G, Sulkes A, Greim G, Peters GJ, van der Born K, Wanders J, de Boer RF, Martin C, Fumoleau P (2002) Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 38: 349-358
4. Carmichael J, Popiela T, Radstone D, Falk S, Borner M, Oza A, Skovsgaard T, Munier S, Martin C (2002) Randomised comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20: 3617-3627
5. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Eng J Med 351: 337-345
6. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947
7. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355: 1041-1047
8. Douillard JY, Hoff PM, Skillings JR, Eisenberg P, Davidson N, Harper P, Vincent MD, Lembersky BC, Thompson S, Maniero A, Benner SE (2002) Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20: 3605-3616
9. Falcone A, Masi G, Allegrini G, Danesi R, Pfanner E, Brunetti IM, Di Paolo A, Cupini S, Del Tacca M, Conte P (2002) Biweekly chemotherapy with oxaliplatin, irinotecan and infusional fluorouracil and leucovorin: a pilot study in patients with metastatic colorectal cancer. J Clin Oncol 20: 4006-4014
10. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Levi F (2000) Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil -leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18: 136-147
11. Giantonio BJ, Catalano PJ, Meropol NJ, Mitchell EP, Schwartz MA, Alberts SR, O'Dwyer PJ, Benson B (2005) High-dose bevacizumab in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J Clin Oncol 2005 ASCO Gastrointestinal Cancers Symposium 23(June 1 Suppl.): 1s (Abstract 169a)
12. Office for National Statistics (2004) Cancer Statistics Registrations: Registrations of Cancer Diagnosed in 2001 England. Series MB1 No. 32 London: Office for National Statistics
13. Maroun JA, Jonker D, Goel R, Christine C, Lister D, Chiritescu G (2006) A phase I/II study of capecitabine (X), irinotecan (I) and oxaliplatin (O) as first-line therapy in patients with advanced or metastatic colorectal cancer. J Clin Oncol 2006 ASCO Annual Meeting Proceedings Part I 24(June 20 Suppl): 18s (Abstract 13540)
14. Petrioli R, Sabatino M, Fiaschi AI, Marsili S, Pozzessere D, Messinese S, Correale P, Civitelli S, Tanzini G, Tani F, De Martino A, Marzocca G, Lorenzi M, Giorgi G, Francini G (2004) UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer. Br J Cancer 90: 306-309
15. Quinn MJ, Babb PJ, Brock A, Kirby EA, Jones J (2001) Cancer Trends in England & Wales 1950-1999. Vol. SMPS No. 66: TSO
16. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343: 905-914
17. Souglakos J, Androulakis N, Syrigos K, Polyzos A, Ziras N, Athanasiadis A, Kakolyris S, Tsousis S, Kouroussis Ch, Vamvakas L, Kalykaki A, Samonis G, Mavroudis D, Georgoulias V (2006) FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 94: 798-805
18. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216
19. Wiseman LR, Adkins JC, Plosker GL, Goa KL (1999) Oxaliplatin: a review of its use in the management of metastatic colorectal cancer. Drugs Aging 14: 459-475